Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I First-in-Human Study of MC001 (ADoBind Dimeric IgG-Monomethyl Auristatin E), a First-in-Class Dimeric Antibody-Drug Conjugate Targeting Folate Receptor Alpha (FRα), in Patients With Advanced Solid Tumours

NCT07929961 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT07929961 Not yet recruiting Phase 1 80 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07929961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, Phase 1, 80 participants (estimated). Lead sponsor National University Hospital, Singapore; Singapore. Primary measures: Incidence of Adverse Events (AEs); Incidence of Serious Adverse Events (SAEs) and 4 more.

How it compares

47 similar trials: same condition (Nasopharyngeal Carcinoma) and phase

Enrollment

This trial
80
Middle half
18 to 91
Median
28
Trials with a value
47

Months from start to completion

This trial
60.5
Middle half
33.6 to 66.1
Median
43.5
Trials with a value
46

Sites

This trial
1
Middle half
1 to 9
Median
1
Trials with a value
42
Posted results or a linked paper 36% 17 of 47 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I First-in-Human Study of MC001 (ADoBind Dimeric IgG-Monomethyl Auristatin E), a First-in-Class Dimeric Antibody-Drug Conjugate Targeting Folate Receptor Alpha (FRα), in Patients With Advanced Solid Tumours
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 16, 2026
Completion date
November 30, 2031
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours, nasopharyngeal carcinoma, pancreatic ductal adenocarcinoma (pdac)

Arms

As registered; 9 arms.

  • Dose Level 1 ExperimentalMC001

    0.3 mg/kg

  • Dose Level 2 ExperimentalMC001

    0.6 mg/kg

  • Dose Level 3 ExperimentalMC001

    1.0 mg/kg

  • Dose Level 4 ExperimentalMC001

    1.6 mg/kg

  • Dose Level 5 ExperimentalMC001

    2.2 mg/kg

+4 more arms

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Incidence of Adverse Events (AEs) From informed consent until 30 days after the last dose of MC001 (approximately 2 years)

    Incidence and severity of adverse events (AEs) occurring during the study period, assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0. CTCAE grades range from Grade 1 (mild) to Grade 5 (death related to an adverse event).

  • Incidence of Serious Adverse Events (SAEs) From screening until end of treatment (up to approximately 2 years)

    Number of participants experiencing one or more serious adverse events (SAEs) during the study period.

  • Incidence of dose-limiting toxicities During Cycle 1 (21 days)

    Number of participants experiencing a dose-limiting toxicity (DLT) during Cycle 1. DLTs are protocol-defined adverse events occurring during the first 21 days of treatment that are considered at least possibly related to the study drug and are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.

  • Maximum Tolerated Dose (MTD) From first dose until completion of dose escalation (up to approximately 24 months)

    The maximum tolerated dose (MTD) is determined using the modified Toxicity Probability Interval (mTPI-2) design and is defined as the highest dose level at which the observed rate of dose-limiting toxicities (DLTs) during Cycle 1 does not exceed the prespecified target toxicity probability.

  • Maximum Administered Dose (MAD) From first dose until completion of dose escalation (up to approximately 24 months)

    The maximum administered dose (MAD) is determined as the highest dose level of MC001 evaluated during the dose-escalation phase, regardless of whether a maximum tolerated dose (MTD) is reached.

+1 more primary endpoint

Lead sponsor's other trials

National University Hospital, Singapore, most recent start first.

Similar trials

Same condition (Nasopharyngeal Carcinoma) and phase, most recent start first.